Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 12 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (4)
P 1 (4)

Trial Status

Unknown5
Completed4
Recruiting1
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07614620Not ApplicableNot Yet Recruiting

Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer

NCT02326064CompletedPrimary

Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4

NCT04707248Phase 1Active Not Recruiting

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

NCT06103916RecruitingPrimary

Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice

NCT02962596CompletedPrimary

EURAD MRI Classification of US Indeterminate Adnexa Lesions

NCT04224467Not ApplicableUnknown

The Application of Real-Time Near-infrared Imaging in Gynecological Surgery

NCT02541370Phase 1Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

NCT01738789UnknownPrimary

EURAD-MR Classification : European Multicenter Study

NCT02580747Phase 1Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

NCT01715168Phase 1Unknown

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

NCT00436189Not ApplicableCompletedPrimary

Assess Cancer in Ovarian Tumors With Biomarkers.

NCT00248820Not ApplicableUnknownPrimary

Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

Showing all 12 trials

Research Network

Activity Timeline